(Q26783543)

1

0 references

Hisako Matsumoto

2

0 references

Shoichiro Ohta

3

0 references

Junya Ono

4

0 references

Masahiro Ogawa

Allergology International

6

0 references

language of work or name

English

0 references

publication date

September 2015

0 references

published in

0 references

volume

64 Suppl

0 references

page(s)

S3-10

0 references

cites work

Analysis of novel disease-related genes in bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Phenotype of asthma related with high serum periostin levels.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Periostin in the bronchial lavage fluid of asthma patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Association of serum periostin with aspirin-exacerbated respiratory disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Innate lymphoid cells in inflammation and immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Periostin is required for maximal airways inflammation and hyperresponsiveness in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Predicting and evaluating response to omalizumab in patients with severe allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Asthma phenotypes: the evolution from clinical to molecular approaches

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Mepolizumab and exacerbations of refractory eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Lebrikizumab treatment in adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Dupilumab treatment in adults with moderate-to-severe atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-gamma and IL-13 production

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Adult asthma biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Cell type-dependent effects of corticosteroid on periostin production by primary human tissue cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

A protective role for periostin and TGF-β in IgE-mediated allergy and airway hyperresponsiveness

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Interleukin-13: central mediator of allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Requirement for IL-13 independently of IL-4 in experimental asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Asthma biomarkers: what constitutes a 'gold standard'?

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Severe asthma in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Using exhaled nitric oxide and serum periostin as a composite marker to identify severe/steroid-insensitive asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Corticosteroid-insensitive asthma: molecular mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

IL-13: a promising therapeutic target for bronchial asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Interleukin-5 and IL-5 receptor in health and diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Periostin in allergic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Serum periostin: a novel biomarker for asthma management

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021

Markers that can Reflect Asthmatic Activity before and after Reduction of Inhaled Corticosteroids: A Pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ALIT.2015.04.012

7 January 2021